These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 9547433)

  • 21. Overall type I error rate and power of multiple Dunnett's tests on rodent body weights in toxicology studies.
    Hoffman WP; Recknor J; Lee C
    J Biopharm Stat; 2008; 18(5):883-900. PubMed ID: 18781523
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Determining the error of dose estimates and minimum and maximum acceptable concentrations from assays with nonlinear dose-response curves.
    Gottschalk PG; Dunn JR
    Comput Methods Programs Biomed; 2005 Dec; 80(3):204-15. PubMed ID: 16256244
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Computer simulations of bioequivalence trials: selection of design and analyte in BCS drugs with first-pass hepatic metabolism: Part II. Non-linear kinetics.
    Fernández-Teruel C; Gonzalez-Alvarez I; Navarro-Fontestad C; García-Arieta A; Bermejo M; Casabó VG
    Eur J Pharm Sci; 2009 Jan; 36(1):147-56. PubMed ID: 19038335
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A statistical evaluation of toxicity study designs for the estimation of the benchmark dose in continuous endpoints.
    Slob W; Moerbeek M; Rauniomaa E; Piersma AH
    Toxicol Sci; 2005 Mar; 84(1):167-85. PubMed ID: 15483190
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ratio estimates, the delta method, and quantal response tests for increased carcinogenicity.
    Bieler GS; Williams RL
    Biometrics; 1993 Sep; 49(3):793-801. PubMed ID: 8241374
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Confidence intervals for the 50 per cent response dose.
    Faraggi D; Izikson P; Reiser B
    Stat Med; 2003 Jun; 22(12):1977-88. PubMed ID: 12802816
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A hierarchical Binomial-Poisson model for the analysis of a crossover design for correlated binary data when the number of trials is dose-dependent.
    Shkedy Z; Molenberghs G; Van Craenendonck H; Steckler T; Bijnens L
    J Biopharm Stat; 2005; 15(2):225-39. PubMed ID: 15796291
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A method for therapeutic dose selection in a phase II clinical trial using contrast statistics.
    Wakana A; Yoshimura I; Hamada C
    Stat Med; 2007 Feb; 26(3):498-511. PubMed ID: 16596575
    [TBL] [Abstract][Full Text] [Related]  

  • 29. On identifying effective and superior drug combinations via Holm's procedure based on the min tests.
    Soulakova JN
    J Biopharm Stat; 2009; 19(2):280-91. PubMed ID: 19212880
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A step-up test procedure to find the minimum effective dose.
    Wang W; Peng J
    J Biopharm Stat; 2015; 25(3):525-38. PubMed ID: 24905396
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Testing for trend with count data.
    Weller EA; Ryan LM
    Biometrics; 1998 Jun; 54(2):762-73. PubMed ID: 9629655
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Empirical Bayes screening of many p-values with applications to microarray studies.
    Datta S; Datta S
    Bioinformatics; 2005 May; 21(9):1987-94. PubMed ID: 15691856
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Some thoughts on the one-sided and two-sided tests.
    Dubey SD
    J Biopharm Stat; 1991; 1(1):139-50. PubMed ID: 1844685
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Three p-value consistent procedures for multiple comparisons with a control in direction-mixed families.
    Kwong KS; Cheung SH; Holland B; Wang Y
    Stat Med; 2007 Oct; 26(23):4253-72. PubMed ID: 17342699
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Dunnett-Bonferroni-based parallel gatekeeping procedure for dose-response clinical trials with multiple endpoints.
    Xu H; Nuamah I; Liu J; Lim P; Sampson A
    Pharm Stat; 2009; 8(4):301-16. PubMed ID: 19065544
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Selection of an adaptive test statistic for use with multiple comparison analyses of neuroimaging data.
    Turkheimer F; Pettigrew K; Sokoloff L; Smith CB; Schmidt K
    Neuroimage; 2000 Aug; 12(2):219-29. PubMed ID: 10913327
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Monte Carlo approach for change-point detection in the Cox proportional hazards model.
    Liu M; Lu W; Shao Y
    Stat Med; 2008 Aug; 27(19):3894-909. PubMed ID: 18254131
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Strategy for genotoxicity testing: hazard identification and risk assessment in relation to in vitro testing.
    Thybaud V; Aardema M; Clements J; Dearfield K; Galloway S; Hayashi M; Jacobson-Kram D; Kirkland D; MacGregor JT; Marzin D; Ohyama W; Schuler M; Suzuki H; Zeiger E;
    Mutat Res; 2007 Feb; 627(1):41-58. PubMed ID: 17126066
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sample size calculation for simulation-based multiple-testing procedures.
    Bang H; Jung SH; George SL
    J Biopharm Stat; 2005; 15(6):957-67. PubMed ID: 16279354
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Optimal adaptive design in clinical drug development: a simulation example.
    Maloney A; Karlsson MO; Simonsson US
    J Clin Pharmacol; 2007 Oct; 47(10):1231-43. PubMed ID: 17906158
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.